Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated japanese patients at high cardiovascular risk - Primary results from the phase 2 YUKAWA study

Circulation Journal

Volumn 78, Issue 5, 2014, Pages 1073-1082

  Hirayama, Atsushi ^a   Honarpour, Narimon ^b   Yoshida, Masayuki ^c   Yamashita, Shizuya ^d   Huang, Fannie ^b   Wasserman, Scott M ^b   Teramoto, Tamio ^e  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AMGEN INC   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

Author keywords

Dyslipidemia; Hypercholesterolemia; Low density lipoprotein cholesterol; PCSK9 antibody

Indexed keywords

APOLIPOPROTEIN B; EVOLOCUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR RISK; CECUM TUMOR; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

EID: 84899633509     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0130     Document Type: Article

References (38)

1. Global Atlas on Cardiovascular Disease Prevention and Control 2011. http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21049&Itemid= (accessed 9 December, 2013).
2. Iso H. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb 2011; 18: 83-88.
3. Imano H, Noda H, Kitamura A, Sato S, Kiyama M, Sankai T, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). Prev Med 2011; 52: 381-386.
4. Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T, Yamashita T. Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol 2000; 29: 837-844.
5. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al. Air Force/Texas Coronary Atherosclerosis Prevention study (AFCAPS/TEXCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87: 1074-1079.
6. Ridker P, MacFadyen J, Fonseca F, Genest J, Gotto A, Kastelein J, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low lowdensity lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009; 2: 616-623.
7. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J 2011; 32: 2525-2532.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
9. Shurtleff D. Some characteristics related to the incidence of cardiovascular disease and death: Framingham study, 18-year follow-up. In: Kannel WB, Gordon T, editors. Washington, D.C.: Department of Health, Education, and Welfare, 1974.
10. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
11. Kurihara Y, Douzono T, Kawakita K, Fujita S, Nachi S, Nagasaka Y. A Large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO® Tablet). Jpn Pharmacol Ther 2007; 35: 9-40.
12. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan: 2012 version. J Atheroscler Thromb 2013; 20: 517-523.
13. Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res 2009; 50: S172-S177.
14. Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009; 106: 9820-9825.
15. Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 2010; 285: 12882-12891.
16. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebocontrolled, phase 2 study. Lancet 2012; 380: 1995-2006.
17. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380: 2007-2017.
18. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126: 2408-2417.
19. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128: 2113-2120.
20. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 2012; 308: 2497-2506.
21. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
22. Robinson J, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, et al. Rationale and design of LAPLACE-2: A phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of AMG 145 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol 2014 January 30, doi:10.1002/clc.22252 [Epub ahead of print].
23. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed 9 December, 2013).
24. Teramoto T, Shaywitz A, Hamilton L, Crispino C, Xu R, Emery M, et al. A phase 1, randomized, double-blind, placebo-controlled study of AMG 145 comparing the pharmacokinetics, pharmacodynamics, and safety in healthy Japanese and Caucasian subjects. In: Proceedings of 45th Annual Scientific Meeting of the Japan Atherosclerosis Society, Tokyo, Japan, 2013.
25. Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies. What cardiologists need to know. Circulation 2013; 127: 2222-2230.
26. Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland L, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
27. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: Weighing the evidence. J Am Coll Cardiol 2012; 60: 875-881.
28. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52- Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial. Circulation 2014; 129: 234-243.
29. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol 2013; 29: 151-167.
30. Grundy SM. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. J Clin Lipidol 2013; 7: 561-565.
31. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-1701.
32. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2013 November 12, doi:10.1161/01.cir.0000437738.63853.7a [Epub ahead of print].
33. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
34. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL Study: A randomized controlled trial. JAMA 2005; 294: 2437-2445.
35. Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Chiang CW, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2. Atherosclerosis 2012; 224: 150-153.
36. Matsue Y, Matsumura A, Suzuki M, Hashimoto Y, Yoshida M. Differences in action of atorvastatin and ezetimibe in lowering lowdensity lipoprotein cholesterol and effect on endothelial function: Randomized controlled trial. Circ J 2013; 77: 1791-1798.
37. Okada K, Kimura K, Iwahashi N, Endo T, Himeno H, Fukui K, et al. Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy: From the viewpoint of cholesterol metabolism. Circ J 2011; 75: 2496-2504.
38. Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). http://clinicaltrials.gov/ct2/show/NCT01764633. (accessed 29 August, 2013).